Call for Abstract

Annual Neurochemistry and Neuropharmacology Congress, will be organized around the theme “Exploring the advances in Neurochemistry and developments in Neuropharmacology”

Neuropharma 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Neuropharma 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Neurological disorders  are sicknesses of the brain, spine and the nerves that connect them. These disorders include Epilepsy, Alzheimer disease and other Dementias, Cerebrovascular diseases including stroke, Parkinson's disease, migraine and other headache disorders, brain tumors, multiple sclerosis, neuroinfections, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition.

The global stroke management market was valued at $19.2 billion in 2013 and nearly $20.2 billion in 2014. This market is expected to reach nearly $28.3 billion by 2019, with a compound annual growth rate (CAGR) of 7% from 2014 to 2019. Epilepsy is a chronic brain disorder. More than 50 million people are affected worldwide. Synchronous brain cell activity causes seizures and depending on the region of brain affected they will produce a range of behaviors. Annually NIH spends $30 billion for medical research, but ½ of 1% is only spent on epilepsy research. Dementia, including Alzheimer’s disease, is one of the biggest global public health challenges facing our generation. Worldwide, at least 44 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 115 million. Much of the increase will be in developing countries like Western Europe and North America. Already 62% of people with dementia live in developing countries. Parkinson’s disease is a dynamic neurological disorder that influences how the individual moves, including how they talk and compose. This disease is caused by low dopamine levels. Various useful treatments, utilizing therapies (physiotherapy), surgery and medications have recognized neurological disorders and changes in the patient group. 

  • Track 1-1Alzheimer disease
  • Track 1-2Epilepsy
  • Track 1-3Multiple sclerosis
  • Track 1-4Stroke
  • Track 1-5Huntington’s disease

Psychiatric Disorders are patterns of behavioral or psychological symptoms that affect various areas of life. Autism is a severe developmental disorder that damages the ability to communicate and interact. Schizophrenia is a brain disorder in which people understand reality abnormally. Dementia is an assembly of thinking and social symptoms that obstructs with daily functioning. The global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%.

  • Track 2-1Depression
  • Track 2-2Bipolar disorder
  • Track 2-3Schizophrenia
  • Track 2-4Autism
  • Track 2-5Dementia

Spinal diseases and spinal disorders often cause pain when bone changes put pressure on the spinal cord or nerves. They can also limit movement. Treatments differ by disease, but sometimes they include back braces and surgery. Spinal disorders are extremely common- it ranges from infants to the elderly; so also spinal trauma. Spinal health has gigantic impact on life. The Neurospinal Disorders track is about diagnostic and therapeutic services for patients suffering from all diseases of the spine and peripheral nerves. There are currently several clinical trials for spinal disorders. Spinal diseases and spinal disorders often cause pain when bone changes put pressure on the spinal cord or nerves. They can also limit movement. Treatments differ by disease, but sometimes they include back braces and surgery. Spinal disorders are extremely common- it ranges from infants to the elderly; so also spinal trauma. Spinal health has gigantic impact on life.

  • Track 3-1Fractures, Compression
  • Track 3-2Kyphosis
  • Track 3-3Spinal Diseases
  • Track 3-4Spinal Fractures
  • Track 3-5Spinal Injuries
  • Track 3-6Spondylolisthesis

Addiction is a condition wherein the person indulges himself in rewarding stimuli, regardless of adverse consequences. Psychopharmacology is the study of effect of drugs which lead to change in behavior. It implicates the modification at molecular level that can be observed in the terms of behavioral changes.

The global market for drugs used in mental disorders was $70.1 billion in 2012 and $68.9 billion in 2013. This market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018.

  • Track 4-1Various types of addiction
  • Track 4-2Role of Epigenetics
  • Track 4-3Addiction and psychology
  • Track 4-4Treatments
  • Track 4-5Diagnostics

Pediatric neuropharmacology deals with the neurological disorders in children such as seizures, delayed speech, weakness, or headaches. ADHD is also a neurodevelopmental disorder, which occurs at the age of six to twelve. The symptoms are excessive activity, inattention, disruptive or impulsive behavior.

Overall, about 40% to 50% of the patients treated in a typical pediatric neurology practice have epilepsy, while 20% have learning difficulties or developmental problems and 20% are suffering from headaches.

  • Track 5-1Attention-deficit disorder
  • Track 5-2Demyelinating disease
  • Track 5-3Neuropathy
  • Track 5-4Developmental and behavioral problems
  • Track 5-5Attention-deficit hyperactivity disorder
  • Track 5-6Neuromuscular diseases
  • Track 5-7Neurocutaneous disorders
  • Track 5-8Genetic Diseases

Neurochemistry deals with the processes occuring within the nervous system and nerve tissues. One of these processes is neurotransmission, wherein, the interaction at the synapse occurs with the help of neurotransmitters such as Dopamine, Acetylcholine, Norepinephrine, Glutamate,  Serotonin, Gamma-amino butyric acid (GABA), Endogenous opioids etc. Activity of ion channels assists neurotransmitter receptors to receive the signals. This mechanism is altered by the many drugs, as a treatment process of neurological disorders.

The global sales of drugs to treat progressive dementia with other neurological abnormalities expected to reach $537.2 million in 2012 and $913.7 million by 2017, at a CAGR of 11.2% over the five-year forecast period.

  • Track 6-1Various Neurotransmitters and their functions
  • Track 6-2Receptors involved in neurotransmission
  • Track 6-3Mechanism of neurotransmission
  • Track 6-4Interaction of neurons and astrocyte
  • Track 6-5Characteristics of Synapses
  • Track 6-6Neuropeptides
  • Track 6-7Effect of drugs on Neurotransmission
  • Track 6-8Influence of Neurochemicals

Neuroinflammation is a hot topic in contemporary neuroscience. Neuroinflammation is inflammation of the nervous tissue. It may be initiated in response to a variety of cues, including infection, traumatic brain injury, toxic metabolites, or autoimmunity. In the central nervous system (CNS), including the brain and spinal cord, microglia are the resident innate immune cells that are activated in response to these cues

  • Track 7-1Stroke rehabilitation
  • Track 7-2Cortical stimulation
  • Track 7-3Recovery from Brain Damage
  • Track 7-4Plasticity
  • Track 7-5Neurophysiotherapy

Neuroimmunology plays an important role in the development of pharmaceutical therapies for various neurological disorders. It constitutes of two complex systems of the body i.e. nervous system and immune system, malfunctioning of either or both can lead to various stress situations. Endocrine and nervous system combines to carry out various physiological activities and their interaction with each other is studied under Neuroendocrinology.

The global G protein, coupled receptors (GPCR) targeting drug market sharply fell in the last three years due to a series of patent expirations of blockbuster products. The market receded from nearly $111 billion to almost $100 billion with a -3.4% compound annual growth rate (CAGR) between 2010 and 2013. With the introduction of novel pharmaceuticals and newly appearing classes of drugs, research expects this market to reach $114 billion by 2018, a CAGR of 2.7% from 2013 to 2018.

Neuropathology is a substantial element of the fundamental study of disease and a foremost field in current medication and diagnosis. The diagnostics is done on the basis of brain/spinal cord tissue, which is received after biopsy. It has been an important tool in the diagnostics of prion disease and mitochondrial disease.

The global market for spinal and neurostimulation intervention products is expected to reach $15.8 billion by 2021 from $12.6 billion in 2016, rising at a compound annual growth rate (CAGR) of 4.5% from 2016 through 2021.

  • Track 8-1Role of Toll like-receptor (TLR4)
  • Track 8-2Neuroimmunological disorders
  • Track 8-3Neuroinflammation
  • Track 8-4Neuropathology of prion diseases
  • Track 8-5Neuro physiotherapy
  • Track 8-6Neuropathology of mitochondrial diseases
  • Track 8-7Neuropathological Diseases

With the advancements in the field of neuroscience, there are many social, ethical and legal issues which have come into picture. From clinical trial of drugs to the application of drugs, from reading of brain to the memory loss, in various psychiatric disorders, ethics are associated with every step. Neuroethics acts as a bridge between science and law. Neuroscience is concerned with all the fields such as structural, molecular, mathematical, computational; developmental which are required to understand brain and its functions. It is an interdisciplinary field which counts on all the aspects of science, required to study nervous system, spinal cord, networking and signalling processes.

The global market for neuromarketing technology reached $21.0 million in 2015. The market is expected to reach $22.0 million by 2021 from $50.3 million in 2016, increasing at a compound annual growth rate (CAGR) of 18.0% from 2016 to 2021.

  • Track 9-1Neuroethical issues
  • Track 9-2Neuroethical principles
  • Track 9-3Case studies
  • Track 9-4Neurobiology and Neuroscience
  • Track 9-5Neurogenesis and Neuroscience
  • Track 9-6Role of Neural circuits

Neuro-Ophthalmology  is the amalgamation of visual system and nervous system. Study suggests that we use almost half of the brain for the vision related activities. Accurate measurement of motor reactions is vital for understanding the occulomotor system. Eye movements provide a window to fundamental brain functions, not only for topographic diagnosis of dysfunctions but also for the knowledge of normal brain function.

  • Track 10-1Brain and visual system
  • Track 10-2Optic neuritis
  • Track 10-3Optic neuropathy
  • Track 10-4Diagnostics and treatments

Neurotoxicity is the result of exposure of the nervous system to the artificial or natural toxic agents. These agents can be heavy metals, drugs, radiations, pesticides or solvents. They work by disrupting the signalling process in between the neurons leading to a bulk of problems. Neurotoxicity has been reported as a major cause behind Alzheimer’s disease, which is a neurodegenerative disorder.

The global market for AD therapeutics and diagnostics by region should reach over $6.2 billion by 2020 from $4.4 billion in 2015, at a compound annual growth rate (CAGR) of 7.1% from 2015 to 2020.

  • Track 11-1Various neurotoxic agents
  • Track 11-2Drug dosage and neurotoxicity
  • Track 11-3Outcome of neurotoxicity
  • Track 11-4Treatments and therapies

Neural repair works on the principle of replacing damaged/infected cells with the healthy cells. Neural stem cells play a vital role in regenerative medication as these are self-renewing and multipotent. These stem cells have proved to be a boon in case of  neurological conditions, such as Huntingdon’s disease, Parkinson's disease and motor neuron disease.

The global stem cell market reached over $5.9 billion in 2015 and will grow from about $6.7 billion in 2016 to nearly $12.3 billion in 2021, registering a compound annual growth rate (CAGR) of 13.1% from 2016 through 2021.

  • Track 12-1Role in treatment
  • Track 12-2Isolation methods
  • Track 12-3Associated ethics
  • Track 12-4Disadvantages
  • Track 12-5Case study

The human brain is one of the most complex thing in the universe, it undergoes conditional change for the entire lifetime of an individual. Later in the 20th century researchers found that the many aspects of the brain can be changed and thus also known as Brain Plasticity.

Some factors can change the neural plasticity of brain through their effects emotionally mostly like thoughts, also can be altered by some serious injuries which can be helpful in certain cases for memory recovery or in case of brain damage and development.

  • Track 13-1Effects and Treatment of Brain Damage
  • Track 13-2Origin of Neuroplasticity
  • Track 13-3Neurobiology and Cortical maps
  • Track 13-4Spasticity or Tonic Paralysis
  • Track 13-5Cognitive Training
  • Track 13-6Sensory prostheses
  • Track 13-7Brain-derived Neurotropic factor

Neuro-stimulants act in a way to improve the neural functioning of the body; generally neuro-stimulants are used in case of fast and healthy recovery of any nervous breakdown or neural damage or brain damage.

The use of neuro-stimulants can either be positive or can also have an adverse effect, but counting on the positives the graph seems to increase for usage of neuro-stimulants, which is proving to be one of the very dependable drugs in the near future.

  • Track 14-1Availability and Applications
  • Track 14-2Neurobehavioral Functioning Data
  • Track 14-3Medication Strategies
  • Track 14-4Working of Neuro-stimulants
  • Track 14-5Prescribing multiple neurostimulants during rehabilitation- safe or unsafe
  • Track 14-6Neurostimulants in Brain Injury